CompanyGOSSNasdaqSan Diego, CA

Gossamer Bio, Inc.

Gossamer Bio develops seralutinib, a small molecule for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Stories only

SEC EDGAR ClinicalTrials.gov gossamerbio.com

SCHEDULE 13D/ASep 28Latest SEC filing

Sep 16Latest story

September 2026

Gossamer Bio adds Greg Ciongoli to board and audit committee

Sep 16PeopleGossamer Bio, Inc.seralutinib

Gossamer Bio files Form D for $150 million offering of rights to acquire securities

Sep 4FinancingGossamer Bio, Inc.

August 2026

Gossamer Bio secures up to $250 million private placement tied to seralutinib milestones

Aug 21Regulatory decisionGossamer Bio, Inc.seralutinib

Gossamer reports Q2 2026 results, reacquires seralutinib rights from Chiesi

Aug 13Quarterly updateGossamer Bio, Inc.seralutinib

July 2026

Gossamer Bio reacquires worldwide seralutinib rights from Chiesi, targets September NDA

Jul 27PartnershipGossamer Bio, Inc.seralutinib

Gossamer Bio stockholders approve charter amendment, incentive plan changes

Jul 14PeopleGossamer Bio, Inc.